
LIST OF TABLES

Table No.	Title	Page
2.1	Prodrugs approved by USFDA in recent past and presently available on the market	24
2.2	Studies indicative of nose-to-brain transport in man	28
2.3	Nose-to-brain transport of drug molecules and possible pathways	34
2.4	Approaches for drug deposition in the olfactory epithelium	45-46
2.5	Example of drug substances for which mice model is explored for nose-to-brain transport studies	57
2.6	Pharmacokinetic data of potential brain-targeted drugs	58
2.7	List of marketed nasal products for brain-targeting	59
2.8	List of investigational drug substances for brain-targeting	60-61
2.9	Comparison of emulsions and microemulsions	64
2.10	Physicochemical properties of Tacrine HCl	83
2.11	Physicochemical properties of Donepezil	87
3.1	Calibration curve of tacrine free base in methanol at 326 nm	118
3.2	Calibration curves of tacrine free base in methanol at 326 nm on different days	119
3.3	Intra day accuracy and precision for tacrine determination	122
3.4	Inter day accuracy and precision for tacrine determination	123
3.5	Interference of excipients observed during estimation of tacrine by UV spectrophotometric method	125
3.6	Calibration curve of donepezil free base in methanol at 313 nm	129
3.7	Calibration curves of donepezil free base in methanol at 313 nm on different days	130
3.8	Intra day accuracy and precision for donepezil determination	133
3.9	Inter day accuracy and precision for donepezil determination	134
3.10	Interference of excipients observed during estimation of donepezil by UV spectrophotometric method	136
4.1	Excipient profiles for four different systems of tacrine microemulsions	149
4.2	Compositions and characterization of tacrine microemulsions system 1 (TME 1)	154
4.3	Compositions and characterization of tacrine microemulsions system 2 (TME 2)	155
4.4	Compositions and characterization of tacrine microemulsions system (TME 3)	156

Table No.	Title	Page
4.5	Compositions and characterization of tacrine microemulsions system 4 (TME 4)	157
4.6	Excipient profiles for four different systems of donepezil microemulsions	160
4.7	Compositions and characterization of donepezil microemulsions system 1 (DME 1)	164
4.8	Compositions and characterization of donepezil microemulsions system (DME 2)	165
4.9	Compositions and characterization of donepezil microemulsions system 3 (DME 3)	166
4.10	Accelerated physical stability of tacrine microemulsions	171
4.11	Accelerated physical stability of donepezil microemulsions	172
4.12	Accelerated chemical stability of tacrine microemulsions at 40°C/75% RH and 30°C/65% RH	174-175
4.13	Accelerated chemical stability of donepezil microemulsions at 40°C/75% RH and 30°C/65% RH	176-177
5.1	Promising compositions of tacrine microemulsions for <i>in vitro</i> diffusion studies	194
5.2	Cumulative % drug diffused for different tacrine microemulsions at different time intervals	194
5.3	Mean flux (µg/min) and diffusion coefficient (cm ² /sec) for different tacrine microemulsions	195
5.4	Regression coefficients of different tacrine microemulsions derived using regressed graphs	196
5.5	Promising compositions of donepezil microemulsions for <i>in vitro</i> diffusion studies	198
5.6	Cumulative % drug diffused for different donepezil microemulsions at different time intervals	198
5.7	Mean flux (µg/min) and diffusion coefficient (cm ² /sec) for different donepezil microemulsions	199
5.8	Regression coefficients of different donepezil microemulsions derived using regressed graphs	200
5.9	Cumulative % drug diffused for different tacrine mucoadhesive microemulsions and solution at different time intervals	203
5.10	Mean flux (µg/min) and diffusion coefficient (cm ² /sec) for different tacrine mucoadhesive microemulsions and solutions	204
5.11	Regression coefficients of different tacrine mucoadhesive microemulsions and solution derived using regressed graphs	204
5.12	Cumulative % drug diffused for different donepezil mucoadhesive microemulsions and solution at different time intervals	206
5.13	Mean flux (µg/min) and diffusion coefficient (cm ² /sec) for different donepezil mucoadhesive microemulsions and solution	207
5.14	Regression coefficients of different donepezil mucoadhesive microemulsions and solution derived using regressed graphs	207

Table No.	Title	Page
6.1	Migration values (R_f) of ^{99m}Tc -pertechnetate, reduced/hydrolyzed (R/H) ^{99m}Tc and ^{99m}Tc -tacrine determined using ascending ITLC (SG) and two different solvent systems	214
6.2	Effect of incubation time on the labeling efficiency of ^{99m}Tc -TS/TME/TMME	214
6.3	<i>In vitro</i> stability of ^{99m}Tc -TS/TME/TMME in 0.90% w/v sodium chloride and mice serum at 37°C	217
6.4	Migration values (R_f) of ^{99m}Tc -pertechnetate, reduced/hydrolyzed (R/H) ^{99m}Tc and ^{99m}Tc -donepezil determined using ascending ITLC (SG) and two different solvent systems	219
6.5	Effect of incubation time on the labeling efficiency of ^{99m}Tc -DS/DME/DMME	219
6.6	<i>In vitro</i> stability of ^{99m}Tc -DS/DME/DMME in 0.90% w/v sodium chloride and mice serum at 37°C	221
6.7	Optimum reaction conditions for radiolabeling of tacrine and donepezil formulations	222
7.1	Tissue/organ distribution of ^{99m}Tc -TS in Balb/c mice at predetermined time intervals post intravenous administration	228
7.2	Tissue/organ distribution of ^{99m}Tc -TS in Balb/c mice at predetermined time intervals post intranasal administration	228
7.3	Tissue/organ distribution of ^{99m}Tc -TME in Balb/c mice at predetermined time intervals post intranasal administration	229
7.4	Tissue/organ distribution of ^{99m}Tc -TMME in Balb/c mice at predetermined time intervals post intranasal administration	229
7.5	Distribution of ^{99m}Tc -TS _{i.v.} , ^{99m}Tc -TS _{i.n.} , ^{99m}Tc -TME _{i.n.} and ^{99m}Tc -TMME _{i.n.} in Balb/c mice [§] at predetermined time intervals	231
7.6	Pharmacokinetics of ^{99m}Tc -TS _{i.v.} , ^{99m}Tc -TS _{i.n.} , ^{99m}Tc -TME _{i.n.} and ^{99m}Tc -TMME _{i.n.} in Balb/c mice	232
7.7	Drug targeting efficiency (DTE (%)) and direct nose to brain transport (DTP (%)) following intranasal administration of ^{99m}Tc -TS/ ^{99m}Tc -TME/ ^{99m}Tc -TMME Formulations	235
7.8	Tissue/organ distribution of ^{99m}Tc -DS in Balb/c mice at predetermined time intervals post intravenous administration	239
7.9	Tissue/organ distribution of ^{99m}Tc -DS in Balb/c mice at predetermined time intervals post intranasal administration	239
7.10	Tissue/organ distribution of ^{99m}Tc -DME in Balb/c mice at predetermined time intervals post intranasal administration	240
7.11	Tissue/organ distribution of ^{99m}Tc -DMME in Balb/c mice at predetermined time intervals post intranasal administration	240
7.12	Distribution of ^{99m}Tc -DS _{i.v.} , ^{99m}Tc -DS _{i.n.} , ^{99m}Tc -DME _{i.n.} and ^{99m}Tc -DMME _{i.n.} in Balb/c mice [§] at predetermined time intervals	242
7.13	Pharmacokinetics of ^{99m}Tc -DS _{i.v.} , ^{99m}Tc -DS _{i.n.} , ^{99m}Tc -DME _{i.n.} and ^{99m}Tc -DMME _{i.n.} in Balb/c mice	243
7.14	Drug targeting efficiency (DTE (%)) and direct nose to brain transport (DTP (%)) following intranasal administration of ^{99m}Tc -DS/ ^{99m}Tc -DME/ ^{99m}Tc -DMME Formulations	244